PT-141
PT-141, also known as bremelanotide, is a synthetic peptide studied for its effects on sexual desire and arousal. Unlike treatments that primarily affect blood flow or hormone levels, PT-141 works through signaling pathways in the brain.
PT-141 AT A GLANCE
WHAT IS PT-141?
PT-141 is a synthetic peptide more formally known as bremelanotide. It was developed from Melanotan II after researchers noticed that the earlier peptide affected sexual response in addition to increasing skin pigmentation.
Researchers modified the original compound to focus more closely on the pathways connected with desire and arousal. PT-141 does not contain a sex hormone and is not designed to raise testosterone or estrogen. Instead, it works through the melanocortin system, a group of signals involved in several functions throughout the body.
HOW DOES PT-141 WORK?
PT-141 activates melanocortin receptors in the brain. These receptors help control communication between brain regions involved in interest, motivation, and sexual response. Researchers believe activity at one receptor in particular, called MC4R, plays an important role in these effects.
This makes PT-141 different from medications that mainly improve circulation. Rather than acting directly on blood vessels, it appears to influence the signals that help begin a sexual response. Researchers are still working to fully understand how those signals differ among individuals.
Areas of Research
PT-141 research explores how brain signaling influences sexual interest and the physical responses that may follow.
SEXUAL DESIRE
Examining whether PT-141 can influence sexual interest and reduce the distress associated with ongoing low desire.
AROUSAL AND PHYSICAL RESPONSE
Studying how signals that begin in the brain may lead to physical arousal throughout the body.
MALE SEXUAL FUNCTION
Exploring erectile response and how PT-141 may work differently from medications that act mainly through blood flow.
MELANOCORTIN SIGNALING
Investigating the receptors and brain pathways that connect desire, motivation, and physical response.
Research Highlights
Early studies of PT-141 examined its effects in both men and women. Trials involving men reported changes in erectile response, while early studies involving women explored desire and arousal. Later clinical trials focused on premenopausal women with acquired, generalized hypoactive sexual desire disorder, often shortened to HSDD. These studies found improvements in sexual desire and distress related to low desire, although the size of the benefit varied among participants.
This research led to the 2019 FDA approval of bremelanotide under the brand name Vyleesi for a specific group of premenopausal women with HSDD. The approval does not include men, postmenopausal women, general performance enhancement, or unregulated PT-141 products.
WHAT IS PT-141 MOST COMMONLY RESEARCHED FOR?
PT-141 is most commonly researched for sexual desire and arousal. Much of the human research has focused on women experiencing a lasting decrease in desire that causes personal distress. Earlier studies also examined erectile response in men, but PT-141 is not currently FDA approved for use in men.
HOW DOES PT-141 FIT INTO PEPTIDE RESEARCH?
PT-141 gives researchers a way to study how small peptide signals can affect desire through the brain. It also shows how an unexpected finding can lead research in a new direction. The sexual-response effects first noticed during Melanotan II studies eventually led scientists to develop PT-141 as a more focused compound.
WHAT MAKES PT-141 UNIQUE?
PT-141 stands out because it does not primarily work by changing hormone levels or directly increasing blood flow. Its effects begin through melanocortin receptors in the brain. This gives researchers another way to explore sexual function beyond the hormone and circulation pathways that are often studied.
HOW IS PT-141 DIFFERENT FROM MELANOTAN II?
PT-141 was developed from Melanotan II, but the two compounds have different research focuses. Melanotan II activates several melanocortin receptors and is strongly associated with pigmentation research. PT-141 was created to place greater emphasis on sexual desire and arousal while reducing its connection with tanning and skin color changes. The two are still related, and PT-141 can affect pigmentation in some cases. However, it is not primarily studied as a pigmentation peptide.
WHAT HAVE RESEARCHERS LEARNED ABOUT PT-141 SO FAR?
Researchers have learned that PT-141 can affect sexual desire and response through brain-based signaling rather than through hormones alone. Controlled studies supported its use for a narrowly defined form of low sexual desire in certain premenopausal women. Research has also identified possible effects such as nausea, flushing, headache, temporary increases in blood pressure, and darkening of certain areas of the skin. These findings are another reason the approved prescription medication should not be treated as interchangeable with unregulated research products.
IS RESEARCH ON PT-141 CONTINUING TODAY?
Yes. Researchers continue exploring how melanocortin receptors influence desire, arousal, motivation, and communication between the brain and body. There is also continued interest in how these pathways may differ between women and men and whether more selective compounds could create targeted effects with fewer unwanted reactions.